The rapid adoption of an ad-supported AI chatbot by a significant portion of U.S. doctors has sparked concerns over its impact on medical decision-making and patient trust. The tool’s creator claims widespread use among physicians, raising questions about whether commercial incentives could influence clinical advice. Critics argue that monetized health advice may undermine the integrity of doctor-patient interactions, while supporters highlight its accessibility in underserved areas. The debate underscores broader tensions between innovation and ethical standards in healthcare technology.
Founder of OpenEvidence chatbot says two-thirds of US physicians use the ad-powered tool, prompting a debate about patient care
